Skip to main content
Top
Published in: BMC Pulmonary Medicine 1/2014

Open Access 01-12-2014 | Case report

Development of microscopic polyangiitis-related pulmonary fibrosis in a patient with autoimmune pulmonary alveolar proteinosis

Authors: Yuhei Kinehara, Hiroshi Kida, Yoshikazu Inoue, Masaki Hirose, Akihiko Nakabayashi, Yoshiko Takeuchi, Yoshitomo Hayama, Kiyoharu Fukushima, Haruhiko Hirata, Koji Inoue, Toshiyuki Minami, Izumi Nagatomo, Yoshito Takeda, Toshiki Funakoshi, Takashi Kijima, Atsushi Kumanogoh

Published in: BMC Pulmonary Medicine | Issue 1/2014

Login to get access

Abstract

Background

Autoimmune pulmonary alveolar proteinosis (aPAP) is a rare lung disease caused by the autoantibody against granulocyte-macrophage colony stimulating factor (GM-CSF). The clinical course of aPAP is variable; in severe cases, patients develop lethal respiratory failure due to pulmonary fibrosis. However, the pathogenesis of pulmonary fibrosis in aPAP has never been delineated.

Case presentation

Here, we describe a rare case of aPAP that was subsequently complicated by microscopic polyangiitis-related pulmonary fibrosis. The patient was a 75-year-old Japanese man diagnosed with aPAP based on the crazy-paving appearance on high-resolution computed tomography (HRCT), “milky” appearance of broncho-alveolar lavage fluid (BALF), and elevated serum levels of the anti-GM-CSF antibody. The patient was followed-up without aPAP-specific treatment for 3 years. During this period, both hematuria and proteinuria appeared; in addition, serum myeloperoxidase (MPO)-anti-neutrophil cytoplasmic antibody (ANCA) turned positive and increased markedly. The second BAL performed one year after the diagnosis, showed that the “milky” appearance had resolved. The HRCT showed that fibrotic changes had developed and that the crazy-paving appearance had disappeared. These data suggest an association between pulmonary fibrosis that developed during the natural course of aPAP and ANCA-related systemic vasculitis.

Conclusion

This is the first case report that suggests the existence of a pathogenetic relationship between ANCA-associated systemic vasculitis and aPAP-related pulmonary fibrosis. The link between ANCA-associated systemic vasculitis and aPAP-related pulmonary fibrosis requires further investigation.
Appendix
Available only for authorised users
Literature
1.
go back to reference Sakagami T, Uchida K, Suzuki T, Carey BC, Wood RE, Wert SE, Whitsett JA, Trapnell BC, Luisetti M: Human GM-CSF autoantibodies and reproduction of pulmonary alveolar proteinosis. N Engl J Med. 2009, 361: 2679-2681. 10.1056/NEJMc0904077.CrossRefPubMedPubMedCentral Sakagami T, Uchida K, Suzuki T, Carey BC, Wood RE, Wert SE, Whitsett JA, Trapnell BC, Luisetti M: Human GM-CSF autoantibodies and reproduction of pulmonary alveolar proteinosis. N Engl J Med. 2009, 361: 2679-2681. 10.1056/NEJMc0904077.CrossRefPubMedPubMedCentral
2.
go back to reference Inoue Y, Trapnell BC, Tazawa R, Arai T, Takada T, Hizawa N, Kasahara Y, Tatsumi K, Hojo M, Ichiwata T, Tanaka N, Yamaguchi E, Eda R, Oishi K, Tsuchihashi Y, Kaneko C, Nukiwa T, Sakatani M, Krischer JP, Nakata K, Japanese Center of the Rare Lung Diseases Consortium: Characteristics of a Large Cohort of Patients with Autoimmune Pulmonary Alveolar Proteinosis in Japan. Am J Respir Crit Care Med. 2008, 177: 752-762. 10.1164/rccm.200708-1271OC.CrossRefPubMedPubMedCentral Inoue Y, Trapnell BC, Tazawa R, Arai T, Takada T, Hizawa N, Kasahara Y, Tatsumi K, Hojo M, Ichiwata T, Tanaka N, Yamaguchi E, Eda R, Oishi K, Tsuchihashi Y, Kaneko C, Nukiwa T, Sakatani M, Krischer JP, Nakata K, Japanese Center of the Rare Lung Diseases Consortium: Characteristics of a Large Cohort of Patients with Autoimmune Pulmonary Alveolar Proteinosis in Japan. Am J Respir Crit Care Med. 2008, 177: 752-762. 10.1164/rccm.200708-1271OC.CrossRefPubMedPubMedCentral
3.
go back to reference Hudson AR, Halprin GM, Miller JA, Kilburn KH: Pulmonary interstitial fibrosis following alveolar proteinosis. Chest. 1974, 65: 700-702. 10.1378/chest.65.6.700.CrossRefPubMed Hudson AR, Halprin GM, Miller JA, Kilburn KH: Pulmonary interstitial fibrosis following alveolar proteinosis. Chest. 1974, 65: 700-702. 10.1378/chest.65.6.700.CrossRefPubMed
4.
go back to reference Miller PA, Ravin CE, Walker Smith GJ, Osborne DR: Pulmonary alveolar proteinosis with interstitial involvement. Am J Roentgenol. 1981, 137: 1069-1071. 10.2214/ajr.137.5.1069.CrossRef Miller PA, Ravin CE, Walker Smith GJ, Osborne DR: Pulmonary alveolar proteinosis with interstitial involvement. Am J Roentgenol. 1981, 137: 1069-1071. 10.2214/ajr.137.5.1069.CrossRef
5.
go back to reference Arbiser ZK, Guidot DM, Pine JR, Giltman LI, Gal AA: Pulmonary alveolar proteinosis mimicking idiopathic pulmonary fibrosis. Ann Diag Pathol. 2003, 7: 82-86. 10.1016/S1092-9134(02)91214-1.CrossRef Arbiser ZK, Guidot DM, Pine JR, Giltman LI, Gal AA: Pulmonary alveolar proteinosis mimicking idiopathic pulmonary fibrosis. Ann Diag Pathol. 2003, 7: 82-86. 10.1016/S1092-9134(02)91214-1.CrossRef
6.
go back to reference Chroneou A, Zias N, Tronic BS, Gonzalez AV, Beamis JF: A case of uncomplicated pulmonary alveolar proteinosis evolving to pulmonary fibrosis. Monaldi Arch Chest Dis. 2007, 67: 234-237.PubMed Chroneou A, Zias N, Tronic BS, Gonzalez AV, Beamis JF: A case of uncomplicated pulmonary alveolar proteinosis evolving to pulmonary fibrosis. Monaldi Arch Chest Dis. 2007, 67: 234-237.PubMed
7.
go back to reference Luisetti M, Bruno P, Kadija Z, Suzuki T, Raffa S, Torrisi MR, Campo I, Mariani F, Pozzi E, Trapnell BC, Mariotta S: Relationship between diffuse pulmonary fibrosis, alveolar proteinosis, and granulocyte-macrophage colony stimulating factor autoantibodies. Respir Care. 2011, 56: 1608-1610. 10.4187/respcare.01054.CrossRefPubMed Luisetti M, Bruno P, Kadija Z, Suzuki T, Raffa S, Torrisi MR, Campo I, Mariani F, Pozzi E, Trapnell BC, Mariotta S: Relationship between diffuse pulmonary fibrosis, alveolar proteinosis, and granulocyte-macrophage colony stimulating factor autoantibodies. Respir Care. 2011, 56: 1608-1610. 10.4187/respcare.01054.CrossRefPubMed
8.
go back to reference Xing Z, Ohkawara Y, Jordana M, Graham F, Gauldie J: Transfer of granulocyte-macrophage colony-stimulating factor gene to rat lung induces eosinophilia, monocytosis, and fibrotic reactions. J Clin Invest. 1996, 97: 1102-1110. 10.1172/JCI118503.CrossRefPubMedPubMedCentral Xing Z, Ohkawara Y, Jordana M, Graham F, Gauldie J: Transfer of granulocyte-macrophage colony-stimulating factor gene to rat lung induces eosinophilia, monocytosis, and fibrotic reactions. J Clin Invest. 1996, 97: 1102-1110. 10.1172/JCI118503.CrossRefPubMedPubMedCentral
9.
go back to reference Rao JK, Weinberger M, Oddone EZ, Allen NB, Landsman P, Feussner JR: The role of antineutrophil cytoplasmic antibody testing in the diagnosis of Wegener granulomatosis. Ann Intern Med. 1995, 123: 925-932. 10.7326/0003-4819-123-12-199512150-00005.CrossRefPubMed Rao JK, Weinberger M, Oddone EZ, Allen NB, Landsman P, Feussner JR: The role of antineutrophil cytoplasmic antibody testing in the diagnosis of Wegener granulomatosis. Ann Intern Med. 1995, 123: 925-932. 10.7326/0003-4819-123-12-199512150-00005.CrossRefPubMed
10.
go back to reference Wiik A: Rational use of ANCA in the diagnosis of vasculitis. Rheumatology (Oxf). 2002, 41: 481-483. 10.1093/rheumatology/41.5.481.CrossRef Wiik A: Rational use of ANCA in the diagnosis of vasculitis. Rheumatology (Oxf). 2002, 41: 481-483. 10.1093/rheumatology/41.5.481.CrossRef
11.
go back to reference Watts R, Lane S, Hanslik T, Hauser T, Hellmich B, Koldingsnes W, Mahr A, Segelmark M, Cohen-Tervaert JW, Scott D: Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis. 2007, 66: 222-227.CrossRefPubMed Watts R, Lane S, Hanslik T, Hauser T, Hellmich B, Koldingsnes W, Mahr A, Segelmark M, Cohen-Tervaert JW, Scott D: Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis. 2007, 66: 222-227.CrossRefPubMed
12.
go back to reference Kallenberg CGM, Heeringa P, Stegeman CA: Mechanisms of disease: pathogenesis and treatment of ANCA-associated vasculitides. Nat Clin Pract Rheumatol. 2006, 2: 661-670.CrossRefPubMed Kallenberg CGM, Heeringa P, Stegeman CA: Mechanisms of disease: pathogenesis and treatment of ANCA-associated vasculitides. Nat Clin Pract Rheumatol. 2006, 2: 661-670.CrossRefPubMed
13.
go back to reference Ito-Ihara T, Muso E, Kobayashi S, Uno K, Tamura N, Yamanishi Y, Fukatsu A, Watts RA, Scott DG, Jayne DR, Suzuki K, Hashimoto H: A comparative study of the diagnostic accuracy of ELISA systems for the detection of anti-neutrophil cytoplasmic antibodies available in Japan and Europe. Clin Exp Rheumatol. 2008, 26: 1027-1033.PubMed Ito-Ihara T, Muso E, Kobayashi S, Uno K, Tamura N, Yamanishi Y, Fukatsu A, Watts RA, Scott DG, Jayne DR, Suzuki K, Hashimoto H: A comparative study of the diagnostic accuracy of ELISA systems for the detection of anti-neutrophil cytoplasmic antibodies available in Japan and Europe. Clin Exp Rheumatol. 2008, 26: 1027-1033.PubMed
14.
go back to reference Basu N, Watts R, Bajema I, Baslund B, Bley T, Boers M, Brogan P, Calabrese L, Cid MC, Cohen-Tervaert JW, Flores-Suarez LF, Fujimoto S, de Groot K, Guillevin L, Hatemi G, Hauser T, Jayne D, Jennette C, Kallenberg CG, Kobayashi S, Little MA, Mahr A, McLaren J, Merkel PA, Ozen S, Puechal X, Rasmussen N, Salama A, Salvarani C, Savage C, et al: EULAR points to consider in the development of classification and diagnostic criteria in systemic vasculitis. Ann Rheum Dis. 2010, 69: 1744-1750. 10.1136/ard.2009.119032.CrossRefPubMed Basu N, Watts R, Bajema I, Baslund B, Bley T, Boers M, Brogan P, Calabrese L, Cid MC, Cohen-Tervaert JW, Flores-Suarez LF, Fujimoto S, de Groot K, Guillevin L, Hatemi G, Hauser T, Jayne D, Jennette C, Kallenberg CG, Kobayashi S, Little MA, Mahr A, McLaren J, Merkel PA, Ozen S, Puechal X, Rasmussen N, Salama A, Salvarani C, Savage C, et al: EULAR points to consider in the development of classification and diagnostic criteria in systemic vasculitis. Ann Rheum Dis. 2010, 69: 1744-1750. 10.1136/ard.2009.119032.CrossRefPubMed
15.
go back to reference Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, Kallenberg CG, St Clair EW, Turkiewicz A, Tchao NK, Webber L, Ding L, Sejismundo LP, Mieras K, Weitzenkamp D, Ikle D, Seyfert-Margolis V, Mueller M, Brunetta P, Allen NB, Fervenza FC, Geetha D, Keogh KA, Kissin EY, Monach PA, Peikert T, Stegeman C, Ytterberg SR, Specks U, RAVE-ITN Research Group: Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010, 363: 221-232. 10.1056/NEJMoa0909905.CrossRefPubMedPubMedCentral Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, Kallenberg CG, St Clair EW, Turkiewicz A, Tchao NK, Webber L, Ding L, Sejismundo LP, Mieras K, Weitzenkamp D, Ikle D, Seyfert-Margolis V, Mueller M, Brunetta P, Allen NB, Fervenza FC, Geetha D, Keogh KA, Kissin EY, Monach PA, Peikert T, Stegeman C, Ytterberg SR, Specks U, RAVE-ITN Research Group: Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010, 363: 221-232. 10.1056/NEJMoa0909905.CrossRefPubMedPubMedCentral
16.
go back to reference Shan SK, Phan NB, Goyal G, Sharma G: Pulmonary alveolar proteinosis in a 67-year-old woman with Wegener’s granulomatosis. J Gen Intern Med. 2010, 25: 1105-1108. 10.1007/s11606-010-1433-7.CrossRef Shan SK, Phan NB, Goyal G, Sharma G: Pulmonary alveolar proteinosis in a 67-year-old woman with Wegener’s granulomatosis. J Gen Intern Med. 2010, 25: 1105-1108. 10.1007/s11606-010-1433-7.CrossRef
17.
go back to reference Selmi C, Lu Q, Humble MC: Heritability versus the role of the environment in autoimmunity. J Autoimmun. 2012, 39: 249-252. 10.1016/j.jaut.2012.07.011.CrossRefPubMed Selmi C, Lu Q, Humble MC: Heritability versus the role of the environment in autoimmunity. J Autoimmun. 2012, 39: 249-252. 10.1016/j.jaut.2012.07.011.CrossRefPubMed
18.
go back to reference Rojas-Villarraga A, Amaya J, Rodriguez A, Mantilla RD, Anaya JM: Introducing polyautoimmunity: secondary autoimmune diseases no longer exist. Autoimmune Dis. 2012, 1: 1-9.CrossRef Rojas-Villarraga A, Amaya J, Rodriguez A, Mantilla RD, Anaya JM: Introducing polyautoimmunity: secondary autoimmune diseases no longer exist. Autoimmune Dis. 2012, 1: 1-9.CrossRef
19.
go back to reference Seymour JF, Preneill JJ: Pulmonary alveolar proteinosis: progress in the first 44 years. Am J Respir Crit Care Med. 2002, 166: 215-235. 10.1164/rccm.2109105.CrossRefPubMed Seymour JF, Preneill JJ: Pulmonary alveolar proteinosis: progress in the first 44 years. Am J Respir Crit Care Med. 2002, 166: 215-235. 10.1164/rccm.2109105.CrossRefPubMed
20.
go back to reference Yashiro M, Muso E, Ito-Ihara T, Oyama A, Hashimoto K, Kawamura T, Ono T, Sasayama S: Significantly high regional morbidity of MPO-ANCA-related angiitis and/or nephritis with respiratory tract involvement after the 1995 great earthquake in Kobe (Japan). Am J Kidney Dis. 2000, 35: 889-895. 10.1016/S0272-6386(00)70260-5.CrossRefPubMed Yashiro M, Muso E, Ito-Ihara T, Oyama A, Hashimoto K, Kawamura T, Ono T, Sasayama S: Significantly high regional morbidity of MPO-ANCA-related angiitis and/or nephritis with respiratory tract involvement after the 1995 great earthquake in Kobe (Japan). Am J Kidney Dis. 2000, 35: 889-895. 10.1016/S0272-6386(00)70260-5.CrossRefPubMed
Metadata
Title
Development of microscopic polyangiitis-related pulmonary fibrosis in a patient with autoimmune pulmonary alveolar proteinosis
Authors
Yuhei Kinehara
Hiroshi Kida
Yoshikazu Inoue
Masaki Hirose
Akihiko Nakabayashi
Yoshiko Takeuchi
Yoshitomo Hayama
Kiyoharu Fukushima
Haruhiko Hirata
Koji Inoue
Toshiyuki Minami
Izumi Nagatomo
Yoshito Takeda
Toshiki Funakoshi
Takashi Kijima
Atsushi Kumanogoh
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Pulmonary Medicine / Issue 1/2014
Electronic ISSN: 1471-2466
DOI
https://doi.org/10.1186/1471-2466-14-172

Other articles of this Issue 1/2014

BMC Pulmonary Medicine 1/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine